

Fig 3. Electrochromatograms for the three family members
The PTPN11 mutation (Thr468Pro, 1403AfiC) was detected in genomic DNA from the leukocytes of the three patients.

119x105mm (300 x 300 DPI)



Fig 4. Histological examination of the biopsy specimen from the face of the second brother Top: Histological examination of a pigmented macule demonstrated slightly elongated rete ridges and epidermal hypermelanosis using Hematoxirin-Eosin staining. Scale bar = 200 μm. Bottom: Higher magnification of the section revealed a hyperpigmented basal layer, incresed numbers of melanocytes without nest formation, and melanophages in the papillary dermis. Masson-fontana ammoniac silver staining. Scale bar = 100 μm.

446x701mm (72 x 72 DPI)

The Journal of Clinical Endocrinology and Metabolism

Copy of e-mail Notification zeg7042

JCEM PROOFS: PLEASE REVIEW YOUR ARTICLE (# 7042)

The Journal of Clinical Endocrinology and Metabolism Published by The Endocrine Society

Dear Author:

Please confirm receipt of this message. There is a short turnaround time to return your corrected page proofs.

RETURNING YOUR PROOF
Please review the instructions below and indicate any necessary changes to your proofs. Keep a copy of the corrected proof for your records, and within 48 hours (two business days) return it to: salbe@cadmus.com. We encourage you to return an annotated PDF by e-mail if possible. You may also fax it to 410-684-2792. If you choose to mail a hard copy, send it within two business days to this address, using a special courier: Erin Salb, Journal Production Manager, 8621 Robert Fulton Drive, Suite 100, Columbia, MD 21046. Delay in returning your page proofs will delay the posting of your revised article online and may result in it being moved to another issue. If you have any questions or require additional time, please contact Erin Salb at salbe@cadmus.com to discuss your article.

Please refer to this URL address
http://rapidproof.cadmus.com/RapidProof/retrieval/index.jsp

Login: your e-mail address
Password: 99Kfw8iUVDBj

The site contains 1 file. You will need to have Adobe Acrobat® Reader software to read the file. This is free software and is available at http://www.adobe.com/products/acrobat/readstep.html.

The file contains a proof of your article scheduled for publication in The Journal of Clinical Endocrinology and Metabolism and a Publication Charge and Reprint Order Form. THE FILE WILL EXPIRE IF NOT DOWNLOADED PROMPTLY, so please be sure to download it immediately. If corrections are not returned promptly, publication of your article could be delayed, so PLEASE REVIEW THE PROOF AND RETURN CORRECTIONS WITHIN 48 HOURS.

REVIEWING YOUR PROOF
After printing the PDF file, please do the following:
- THOROUGHLY PROOFREAD ALL TEXT AS WELL AS ANY FIGURES, TABLES, and EQUATIONS to ensure that all elements are present and accurate and that any Greek and other special characters have translated correctly.
- Indicate changes or corrections in the margin of the page proofs. To ensure accuracy in the rendering of your corrections, please provide a typed list including all corrections and responses to queries.
- Answer all queries (which are denoted in the margin near the relevant line as AQ:A, AQ:B, AQ:C, etc. and are listed on the last page of the PDF proof; other marks in the margin such as T1, F1, and Fn1 denote citations of tables, figures, and footnotes, respectively, and do not require any action on your part). NOTE THAT NOT ALL CHANGES ARE POINTED OUT IN THE QUERIES, SO IT IS CRUCIAL THAT YOU REVIEW YOUR PROOF CAREFULLY.
- Note that this is a low-resolution proof and figure quality might therefore seem diminished. The file that will be used for printing is of a higher resolution. However, if you have any concerns about the quality of

your figures, please note your concerns on the relevant page. If a correction to a figure is required, please submit a revised digital file that meets the requirements described at http://cpc.cadmus.com/da/index.jsp. Also include a good-quality hard copy of the corrected figure.

PUBLISH-AHEAD-OF-PRINT
Your paper will publish online ahead of the print publication in its final version without page numbers. The date the paper appears online is the publication date of record. Please Note: delays in submitting corrections will delay the online publish-ahead-of-print posting of the article.

REPRINT ORDER FORM AND PUBLICATION CHARGES
All regular articles are subject to publication charges. Only those articles invited for publication by the Editor-in-Chief are exempt from charges. The Reprint Order Form should be signed and completed, even if your paper was invited and even if you are not ordering reprints. Send the completed form to: The Endocrine Society, c/o Bank of America, P.O. Box 631048, Baltimore, Maryland 21263-1048. Do not send page proofs to this address.

Sincerely,

Erin Salb
Journal Production Manager
Cadmus Communications, a Cenveo company
Publisher Services Group
8621 Robert Fulton Drive, Suite 100
Columbia, Maryland 21046
Telephone: 410-691-6489
FAX: 410-684-2792
E-mail: salbe@cadmus.com

The Journal of Clinical Endocrinology & Metabolism Reprint and Publication Charges 2009

This is your publication fee and reprint order form or pro forma invoice

Reprint order forms and purchase orders or payments must be received 72 hours after receipt of form either by mail or by fax at 877-705-1373. It is the policy of Cadmus Reprints to issue one invoice per order.

Please print clearly. Please return this form whether reprints are ordered or not.

Please keep a copy of this document for your records

Author Name: Sumito Dateki, Kitaro Kosaka, Kosei Hasegawa, Hiroyuki Tanaka, Noriyuki Azuma, Susumu Yokoya, Koji Muroya, Masanori Adachi, Toshihiro Tajima, Katsuaki Motomura, Eiichi Kinoshita, Hiroyuki Moriuchi, Naoko Sato, Maki Fukami, and Tsutomu Ogata

Title of Article: Heterozygous OTX2 Mutations Are Associated with Variable Pituitary Phenotype

Issue of Journal: 95(2) Reprint # 3553184 Manuscript # 09-1334 Publication Date February 2010

Number of Pages: 9 Color in Article? (Yes) / No (Please Circle) Symbol JCEM

Please include the journal name and reprint number or manuscript number on your purchase order or other correspondence.

Order and Shipping Information

Reprint Costs (Please see page 2 of 2 for reprint costs/fees.)

____	Number of reprints ordered	$ ____
200	Number of color reprints ordered	$ 1,228
____	Number of covers ordered	$ ____
	Subtotal	$ 1,228
	(See instructions on page 2)	
	Taxes	$ 0
	First address included, add $32 for each additional shipping address	$ ____

Publication Fees

Membership Number 204509

	Page Charges:	
	Member: **$90 per** journal page	$ 810
	Non-member: **$110 per** journal page	$ ____
4	Number of color figures	
	Color in journal: TES members add **$235 per** color figure, TES non-members add **$735 per** color figure	$ 940
	Wellcome Trust Option **($3,000)**	$ ____

http://www.endo-society.org/journals/AuthorInfo/wellcometrust.cfm

Total Reprint Costs & Publication Fees: Total Due $ 2,978

Note: A FINAL invoice will be sent after publication

Shipping Address (cannot ship to a P.O. Box) Please Print Clearly

Name Tsutomu Ogata
Institution National Research Institute for Child Health and Development
Street 2-10-1 Ohkura, Setagaya
City Tokyo State ____ Zip 157-8535
Country Japan
Quantity ____ Fax +81-3-5494-7026
Phone: Day +81-3-5494-7025 Evening +81-3-5494-7025
E-mail Address tomogata@nch.go.jp

Additional Shipping Address* (cannot ship to a P.O. Box)
Please Print Clearly

Name ____
Institution ____
Street ____
City ____ State ____ Zip ____
Country ____
Quantity ____ Fax ____
Phone: Day ____ Evening ____
E-mail Address ____

** Add $32 for each additional shipping address*

Payment and Credit Card Details

A. Checks must be paid in U.S. dollars and drawn on a U.S. Bank.
B. Purchase Order No. ____
Please fax P.O. to: 877-705-1373
C. Credit Card: ___X VISA _____Am. Exp. _____ MasterCard
Card Number 4541 5403 5493 6000
Expiration Date 10/2013
Signature: ____

Please send your order form and purchase order or prepayment made payable to:

The Endocrine Society
P.O. Box 17027
Baltimore, MD 21297-0240

Note: Do not send express packages to this location.

Billing Address

Please Print Clearly

Please complete billing address as it appears on credit card statement

Name Tsutomu Ogata
Institution National Research Institute for Child Health and Development
Department Department of Endocrinology and Metabolism
Street 2-10-1 Ohkura, Setagaya
City Tokyo State ____ Zip 157-8535
Country Japan
Phone +81-3-5494-7025 Fax +81-3-5494-7026
E-mail Address tomogata@nch.go.jp

Cadmus will process credit cards and *Cadmus Journal Services* will appear on the credit card statement. We reserve the right to adjust payment to the final invoice amount.

If you do not mail your order form, you may fax it to 877-705-1373 with your credit card information.

Signature ____ Date 26 November 2009

Signature is required. By signing this form, the author agrees to accept personal responsibility for the payment of reprints and/or all charges described in this document.

PB 7-30-09

The Journal of Clinical Endocrinology & Metabolism

2009 REPRINT AND PUBLICATION CHARGES

Black and White Reprint Prices

Domestic (USA only)					
# of Pages	100	200	300	400	500
1-4	$306	$347	$397	$434	$475
5-8	$498	$568	$658	$738	$807
9-12	$673	$784	$915	$1,032	$1,144
13-16	$848	$999	$1,181	$1,322	$1,474
17-20	$1,035	$1,209	$1,440	$1,620	$1,798
Covers	$154	$187	$225	$264	$310

International (includes Canada and Mexico)					
# of Pages	100	200	300	400	500
1-4	$343	$395	$451	$500	$558
5-8	$542	$633	$746	$849	$949
9-12	$726	$875	$1,042	$1,191	$1,342
13-16	$917	$1,107	$1,340	$1,529	$1,728
17-20	$1,113	$1,341	$1,639	$1,873	$2,111
Covers	$161	$206	$254	$302	$352

Minimum order is 100 copies. Maximum order using this form is 500 copies. For articles longer than 20 pages, please consult Cadmus Reprints at 410-943-0629. For orders larger than 500 copies, contact Pete Brown (tel) 410-943-3095, (fax) 877-705-1373, brownp@cadmus.com.

Reprint Cover

Cover prices are listed above. The cover will include the publication title, article title, and author name printed in black.

Publication Fees

Page and color charges are assessed based on the year of submission. For manuscripts submitted before 2009, go to http://www.endo-society.org/journals/authorinfo/index.cfm and click on Author Page and Color Charges.

Page Charges

TES Members add **$90.00** per journal page for all pages in the article. Non-TES Members add **$110.00** per journal page for all pages in the article. Page charges are not levied for papers specifically invited by the Editor-in-Chief.

Articles Published with Color Figures

Please state the exact color figure charge on page 1 and add to your payment or purchase order accordingly. (Author color charges do not apply to authors of invited papers, provided the photographs have been approved by the Editor-in-Chief.)

Shipping

Shipping costs are included in the reprint prices. Domestic orders are shipped via FedEx Ground service. Foreign orders are shipped via a proof of delivery air service. The shipping address printed on an institutional purchase order always supersedes other addresses. Orders can be shipped to more than one location. There is an additional charge for each additional location.

Color Reprint Prices

Domestic (USA only)					
# of Pages	100	200	300	400	500
1-4	$410	$545	$696	$836	$976
5-8	$600	$770	$958	$1,137	$1,308
9-12	$775	$981	$1,216	$1,430	$1,643
13-16	$950	$1,198	$1,479	$1,721	$1,972
17-20	$1,132	$1,410	$1,740	$2,018	$2,295
Covers	$154	$187	$225	$264	$310

International (includes Canada and Mexico)					
# of Pages	100	200	300	400	500
1-4	$494	$664	$870	$1,044	$1,235
5-8	$715	$960	$1,199	$1,428	$1,646
9-12	$952	$1,228	$1,532	$1,793	$2,065
13-16	$1,171	$1,503	$1,857	$2,161	$2,476
17-20	$1,406	$1,772	$2,186	$2,534	$2,877
Covers	$161	$206	$254	$302	$352

Delivery

Your order will be shipped within 2 weeks of the journal print date. Allow extra time for delivery.

Late Order Charges

Articles more than 90 days from publication date will carry an additional charge of $5.83 per page for file retrieval.

Tax Due

Residents of the following localities are to add sales tax to each reprint order as outlined below

District of Columbia	5.75%
Maryland	6%
Pennsylvania	6%
Virginia	5%
Canadian GST	5%

Publishing Requirements

The Endocrine Society requires prepayment or a signed institutional purchase order covering the full amount of your page charges, color charges, and reprint charges before your article will be published. You must return this form with payment of page and color charges even if you are not ordering reprints. Return this order form with check, credit card information, or signed purchase order to:

The Endocrine Society
P.O. Box 17027
Baltimore, MD 21297-0240

Note: Do not send express packages to this location.

Please direct all inquiries to:

Pete Brown
866-487-5625 (toll free number)
410-943-3095 (direct number)
877-705-1373 (FAX number)
brownp@cadmus.com

PB 7-30-09

Instructions for Annotating Your .PDF Proof

- Use Text Boxes and the Callout Tool to indicate changes to the text.



- Use the Strike-Out tool to indicate deletions to the text.

- Use the Highlighting Tool to indicate font problems, bad breaks, and other textual inconsistencies.



- Clearly indicate where changes need to be made using arrow, lines, and the Call-Out Tool.



- Mark changes and answer queries in the margins and other areas of white space.



- Avoid obscuring the text with corrections.



balt1/zeg-jcem/zeg-jcem/zeg00210/zeg7042-10z | xppws | S=1 | 11/24/09 | 9:20 | 4/Color Figure(s): F1–4 | Art: 09-1334 | Input-ss

Heterozygous Orthodenticle Homeobox 2 Mutations Are Associated with Variable Pituitary Phenotype

Sumito Dateki, Kitaro Kosaka, Kosei Hasegawa, Hiroyuki Tanaka, Noriyuki Azuma, Susumu Yokoya, Koji Muroya, Masanori Adachi, Toshihiro Tajima, Katsuaki Motomura, Eiichi Kinoshita, Hiroyuki Moriuchi, Naoko Sato, Maki Fukami, and Tsutomu Ogata

Department of Endocrinology and Metabolism (S.D., N.S., M.F., T.O.), National Research Institute for Child Health and Development, and Division of Ophthalmology (N.A.) and Department of Medical Subspecialties (S.Y.), National Children's Medical Center, Tokyo 157-8535, Japan; Department of Pediatrics (S.D., K.M., E.K., H.M.), Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan; Department of Pediatrics (K.K.), Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan; Department of Pediatrics (K.H., H.T.), Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan; Division of Endocrinology and Metabolism (K.M., M.A.), Kanagawa Children's Medical Center, Yokohama 232-8555, Japan; and Department of Pediatrics (T.T.), Hokkaido University School of Medicine, Sapporo 060-8638, Japan

Context: Although recent studies have suggested a positive role of *OTX2* in pituitary as well as ocular development and function, detailed pituitary phenotypes in *OTX2* mutations and *OTX2* target genes for pituitary function other than *HESX1* and *POU1F1* remain to be determined.

Objective: We aimed to examine such unresolved issues.

Subjects: We studied 94 Japanese patients with various ocular or pituitary abnormalities.

Results: We identified heterozygous p.K74fsX103 in case 1, p.A72fsX86 in case 2, p.G188X in two unrelated cases (3 and 4), and a 2,860,561-bp microdeletion involving *OTX2* in case 5. Clinical studies revealed isolated GH deficiency in cases 1 and 5; combined pituitary hormone deficiency in case 3; abnormal pituitary structures in cases 1, 3, and 5; and apparently normal pituitary function in cases 2 and 4, together with ocular anomalies in cases 1–5. The wild-type Orthodenticle homeobox 2 (OTX2) protein transactivated the *GNRH1* promoter as well as the *HESX1*, *POU1F1*, and *IRBP* (interstitial retinoid-binding protein) promoters, whereas the p.K74fsX103-OTX2 and p.A72fsX86-OTX2 proteins had no transactivation functions and the p.G188X-OTX2 protein had reduced (~50%) transactivation functions for the four promoters, with no dominant-negative effect. cDNA screening identified positive *OTX2* expression in the hypothalamus.

Conclusions: The results imply that *OTX2* mutations are associated with variable pituitary phenotype, with no genotype-phenotype correlations, and that *OTX2* can transactivate *GNRH1* as well as *HESX1* and *POU1F1*. (***J Clin Endocrinol Metab* 95: 0000–0000, 2010**)

Pituitary development and function depends on the spatially and temporally controlled expression of multiple transcription factor genes such as *POU1F1*, *HESX1*, *LHX3*, *LHX4*, *PROP1*, and *SOX3* (1, 2). Whereas mutations of some genes (*e.g. POU1F1*) result in a relatively characteristic pattern of pituitary hormone deficiency, those of other genes (*e.g. HESX1*) are associated with a wide range of pituitary phenotype including combined pi-

ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.

doi: 10.1210/jc.2009-1334 Received June 23, 2009. Accepted November 9, 2009.

Abbreviations: CGH, Comparative genomic hybridization; CPHD, combined pituitary hormone deficiency; EPP, ectopic posterior pituitary; FISH, fluorescence *in situ* hybridization; HD, homeodomain; IGHD, isolated GH deficiency; IRBP, interstitial retinoid-binding protein; MLPA, multiplex ligation-dependent probe amplification; NMD, nonsense mediated mRNA decay; OTX2, orthodenticle homeobox 2; PH, pituitary hypoplasia; SOD, septooptic dysplasia; TD, transactivation domain.

tuitary hormone deficiency (CPHD), isolated GH deficiency (IGHD), and apparently normal phenotype. However, because mutations of these genes account for a relatively minor portion of patients with congenital hypopituitarism (2, 3), multiple genes would remain to be identified in congenital hypopituitarism.

Orthodenticle homeobox 2 (*OTX2*) is a transcription factor gene primarily involved in ocular development (4). It encodes a paired type homeodomain (HD) and a transactivation domain (TD) and produces two functionally similar splice variants, isoform-a (GenBank accession no. NM_21728.2) and isoform-b (NM_172337.1) with and without eight amino acids because of alternative splice acceptor sites at the boundary of intron 3 and exon 4 (5). To date, at least 10 pathological heterozygous *OTX2* mutations have been identified in patients with ocular malformations such as anophthalmia and/or microphthalmia (6, 7). Ocular phenotype is highly variable, ranging from anophthalmia to nearly normal eye development, even in patients from the same family. Furthermore, most patients also exhibit brain anomaly, seizure, and/or developmental delay.

Recent studies have indicated that *OTX2* is also involved in pituitary development and function. Dateki *et al.* (8) showed that *OTX2* is expressed in the pituitary and has a transactivation function for the promoters of *POU1F1* and *HESX1* as well as the promoter of *IRBP* (interstitial retinoid-binding protein) involved in ocular function and that a frameshift *OTX2* mutation identified in a patient with bilateral anophthalmia and partial IGHD barely retained the transactivation activities. Subsequently a missense *OTX2* mutation with a dominant-negative effect and a frameshift *OTX2* mutation with loss-of-function effect were identified in CPHD patients with and without ocular malformation (9, 10).

However, detailed pituitary phenotypes in *OTX2* mutation-positive patients as well as other possible *OTX2* target genes for pituitary development and function remain to be determined. Here we report five new patients with *OTX2* mutations and summarize clinical findings in *OTX2* mutation-positive patients. We also show that *OTX2* is expressed in the hypothalamus and has a transactivation function for the promoter of *GNRH1*.

Patients and Methods

Patients

We studied 94 Japanese patients consisting of: 1) 16 patients with ocular anomalies and pituitary dysfunctions accompanied by short stature (<−2 SD) (six with anophthalmia and/or microphthalmia and CPHD, five with anophthalmia and/or microphthalmia and IGHD, three with septooptic dysplasia (SOD) and CPHD, and two with SOD and IGHD) (group 1); 2) 12 patients with ocular anomalies whose pituitary functions were not investigated (one with bilateral microphthalmia and short stature, one with bilateral optic nerve hypoplasia and short stature, and 10 with anophthalmia and/or microphthalmia and normal stature) (group 2); and 3) 66 patients with pituitary dysfunctions but without ocular anomalies (five with IGHD and 61 patients with CPHD) (group 3). No demonstrable mutation was identified for *HESX1* in patients with SOD, *GH1* and *HESX1* in patients with IGHD, and *POU1F*, *HESX1*, *LHX3*, *LHX4*, *PROP1*, and *SOX3* in patients with various types of CPHD (2). All the patients had normal karyotype.

Primers and probes

The primers and probes used in this study are shown in supplemental Table S1, published as supplemental data on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org.

Sequence analysis of OTX2

This study was approved by the Institutional Review Board Committee at National Center for Child Health and Development. After obtaining written informed consent, the coding exons 3-5 and their flanking splice sites were PCR amplified using leukocyte genomic DNA samples of all 94 patients and were subjected to direct sequencing on a CEQ 8000 autosequencer (Beckman Coulter, Fullerton, CA). To confirm a heterozygous mutation, the corresponding PCR products were subcloned with TOPO TA cloning kit (Invitrogen, Carlsbad, CA), and normal and mutant alleles were sequenced separately.

Prediction of the occurrence of aberrant splicing and nonsense mediated mRNA decay (NMD)

To examine whether identified mutations could cause aberrant splicing by creating or disrupting exonic splicing enhancers and/or splice sites (11, 12), we performed *in silico* analyses with the ESE finder release 3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) for the prediction of exonic splice enhancers and with the program at the Berkeley Drosophila Genome Project (http://www.fruitfly.org/seq_tools/splice.html) for the prediction of splice sites. We also analyzed whether identified mutations could be subject to NMD on the basis of the previous report (12, 13).

Deletion analysis

Multiplex ligation-dependent probe amplification (MLPA) was performed for *OTX2* intragenic mutation-negative patients as a screening of a possible microdeletion affecting *OTX2*. This procedure was performed according to the manufacturer's instructions (14), using probes designed specifically for *OTX2* exon 4 together with a commercially available MLPA probe mix (P236) (MRC-Holland, Amsterdam, The Netherlands) used as internal controls. To confirm a microdeletion, fluorescence *in situ* hybridization (FISH) was performed with a long PCR product for *OTX2* (a 6096 bp segment from intron 2 to exon 5) together with an RP11-56612 BAC probe used as an internal control. The probe for *OTX2* was labeled with digoxigenin and detected by rhodamine antidigoxigenin, and the control probe was labeled with biotin and detected by avidin conjugated to flu-

AQ: A

Please change the words for "an RP11-566I2 BAC probe (14q11.2; Invitrogen, Carlsbad, CA)".



FIG. 1. Sequence analysis in cases 1–4. A, The structure of *OTX2* (the isoform-b) and the position of the mutations identified. The *black* and *white boxes* on genomic DNA (gDNA) denote the coding regions on exons 1-5 (E1-E5) and the untranslated regions, respectively. *OTX2* encodes the HD (a *blue region*), the SIWSPA conserved motif (an *orange region*), and the two tandem tail motifs (*green triangles*). The TD (a *gray triangle*) is assigned to the C-terminal side; deletion of each tail motif reduces the transactivation function, and that of a region distal to the SIWSPA motif further reduces the transactivation function. In addition, another TD may also reside in the 5′ side of the HD (17). The three mutations identified in this study are shown. B, Electrochromatograms showing the mutations in cases 1–4. Shown are the direct sequences and subcloned normal and mutant sequences. The deleted sequences are shaded in *gray*, and the inserted sequence is highlighted in *yellow*. The mutant and the corresponding wild-type nucleotides are indicated by *red asterisks*.

orescein isothiocyanate. To indicate an extent of a microdeletion, oligoarray comparative genomic hybridization (CGH) was carried out with 1×244K human genome array (catalog no. G4411B; Agilent Technologies, Palo Alto, CA), according to the manufacturer's protocol. Finally, to characterize a microdeletion, long PCR was performed with primer pairs flanking the deleted region, and a long PCR product was subjected to direct sequencing using serial sequence primers. The deletion size and the junction structure were determined by comparing the obtained sequences with the reference sequences at the National Center for Biotechnology Information Database (NC_000014.7; Bethesda, MD), and the presence or absence of repeat sequences around the breakpoints was examined with Repeatmasker (http://www.repeatmasker.org).

Functional studies

Western blot analysis, subcellular localization analysis, DNA binding analysis, and transactivation analysis were performed by the previously reported methods (8) (for details, see supplemental methods). In this study, we used the previously reported expression vector and fluorescent vector containing the wild-type *OTX2* cDNA; the probes with the wild-type and mutated OTX2 binding sites within the *IRBP*, *HESX1*, and *POU1F1* promoter sequences; and the luciferase reporter vectors containing the *IRBP*, *HESX1*, and *POU1F1* promoter sequences (8). We further created expression vectors and fluorescent vectors containing mutant *OTX2* cDNAs by site-directed mutagenesis using Prime STAR mutagenesis basal kit (Takara, Otsu, Japan), and constructed a 30-bp probe with wild-type (TAATCT) and mutated (TGGGCT) putative OTX2 binding site within the *GNRH1* promoter sequence and a luciferase reporter vector containing the *GNRH1* promoter sequence (−1349 to −1132 bp) by inserting the corresponding sequence into pGL3 basic. The *GNRH1* promoter sequence was based on the report of Kelley *et al.* (15). Transfections were performed in triplicate within a single experiment, and the experiment was repeated three times.

PCR-based expression analysis of *OTX2*

Human cDNA samples were purchased from CLONTECH (Palo, Alto, CA) except for leukocyte and skin fibroblast cDNA samples that were prepared with Superscript III reverse transcriptase (Invitrogen). PCR amplification was performed for the cDNA samples (0.5 ng), using the primers hybridizing to exon 3 and 4 of *OTX2* and those hybridizing to exons 2/3 and 4/5 (boundaries) of *GAPDH* used as an internal control.

Results

Identification of mutations and substitutions

Three novel heterozygous *OTX2* mutations were identified in four cases, *i.e.* a 16-bp deletion at exon 4 that is predicted to cause a frameshift at the 74th codon for lysine and resultant termination at the 103rd codon (c.221_236del16, p.K74fsX103) in case 1; a 4-bp deletion and a 2-bp insertion at exon 4 that is predicted to cause a frame shift at the 72nd codon for alanine and resultant termination at the 86th codon (c.214_217delGCACinsCA, p.A72fsX86) in case 2; and a nonsense mutation at exon 5 that is predicted to cause a substitution of the 188th glycine with stop codon (c.562G>T, p.G188X) in two unrelated cases (3 and 4; Fig. 1). In addition, heterozygous missense substitutions F1
were identified in patient 1 (c.532A>T, p.T178S) and patient 2 (c.734C>T, p.A245V). Cases 1 and 3 were from group 1, cases 2 and 4 and patient 2 were from group 2, and patient 1 was from group 3. Parental analysis indicated that frameshift mutations in cases 1 and 2 were absent from the parents (*de novo* mutations), whereas the missense substitution of patient 2 was inherited from phenotypically normal father. The parents of cases 3 and 4 and patient 1 refused molecular studies. All the mutations and the missense substitutions were absent from 100 control subjects.

Prediction of the occurrence of aberrant splicing and NMD

The two frameshift mutations and the nonsense mutation were predicted to influence neither exonic splice enhancers nor splice donor and acceptor sites (supplemental Tables S2 and S3). Furthermore, the two frameshift mutations were predicted to produce the premature termination codons on the mRNA transcribed from the last exon

balt1/zeg-jcem/zeg-jcem/zeg00210/zeg7042-10z | xppws | S=1 | 11/24/09 | 9:20 | 4/Color Figure(s): F1–4 | Art: 09-1334 | Input-ss

COLOR



FIG. 2. Deletion analysis in case 5. A, MLPA analysis. The *red asterisk* indicates peaks for the *OTX2* exon 4, and the *black arrows* indicate control peaks. The *red peaks* indicate the internal size markers. Deletion of the MLPA probe binding site is indicated by the reduced peak height. B, FISH analysis. The probe for *OTX2* detects only a *single red signal* (an *arrow*), whereas the RP11-56612 BAC probe identifies *two green signals* (*arrowheads*). C, Oligoarray CGH analysis and direct sequencing of the deletion junction. The deletion is 2,860,561 bp in physical size (shaded in *gray*) and is associated with an addition of a 931-bp segment (highlighted in *yellow*). The normal sequences flanking the microdeletion are indicated with *dashed underlines*.

Please change RP11-56612 for RP11-566I2.

5, indicating that the frameshift mutations as well as the nonsense mutation had the property to escape NMD (supplemental Fig. S1).

Identification of a microdeletion

A heterozygous microdeletion affecting *OTX2* was indicated by MLPA and confirmed by FISH in case 5 of group 1 (Fig. 2, A and B). Oligoarray CGH delineated an approximately 2.9-Mb deletion, and sequencing of the fusion point showed that the microdeletion was 2,860,561 bp in physical size (56,006,531–58,867,091 bp on the NC_000014.7) and was associated with an addition of a complex 931-bp segment consisting of the following structures (cen → tel): 2 bp (TA) insertion → 895 bp sequence identical with that in a region just centromeric to the microdeletion (55, 911, 347–55, 912, 241 bp) → 1 bp (C) insertion → 33-bp sequence identical with that within the deleted region (58, 749, 744–58, 749, 776 bp) (Fig. 2C). Repeat sequences were absent around the break points. This microdeletion was not detected in DNA from the parents.

Functional studies of the wild-type and mutant OTX2 proteins

Western blot analysis detected wild-type OTX2 protein of 31.6 kDa and mutant OTX2 proteins of 11.5 kDa (p.K74fsX103), 9.7 kDa (p.A72fsX86), and 15.4 kDa (p.G188X) (Fig. 3A). The molecular masses were as predicted from the mutations. The band intensity was



FIG. 3. Functional studies. A, Western blot analysis. Both WT and MT1-MT3 OTX2 proteins are detected with different molecular masses (*arrows*). WT, Wild type; MT1, p.K74fsX103; MT2, p.A72fsX86; and MT3, p.G188X. B, Subcellular localization analysis. Whereas green fluorescent protein (GFP) alone is diffusely distributed throughout the cell, the GFP-fused WT-OTX2 and MT3-OTX2 proteins localize to the nucleus. By contrast, the GFP-fused MT1-OTX2 and MT2-OTX2 proteins are incapable of localizing to the nucleus. C, DNA binding analysis using the wild-type (WT) and mutated (MT) probes derived from the promoters of *IRBP*, *HESX1*, *POU1F1*, and *GNRH1*. The symbols (+) and (−) indicate the presence and absence of the corresponding probes, respectively. Both WT and MT3 OTX2 proteins bind to the WT but not the MT probes. For the probe derived from the *IRBP* promoter, two shifted bands are found for both WT-OTX2 and MT3-OTX2 proteins as reported previously (17). S, Shifted bands; F, free probes. D, Transactivation analysis, using the promoter sequences of *IPBP*, *HESX1*, *POU1F1*, and *GNRH1*. The results are expressed using the mean and SD. The *black*, *blue*, *red*, and *green bars* indicate the data of the empty expression vectors (0.6 μg), expression vectors with WT *OTX2* cDNA (0.6 μg), expression vectors with MT1-MT3 *OTX2* cDNAs (0.6 μg), and the mixture of expression vectors with WT (0.3 μg) and those with MT1-MT3 *OTX2* cDNAs (0.3 μg), respectively; thus, the same amount of expression vectors has been used for each assay.

comparable between the wild-type OTX2 protein and the p.G188X-OTX2 protein and was faint for the p.K74fsX103-OTX2 and p.A72fsX86-OTX2 proteins.

Subcellular localization analysis showed that the p.G188X-OTX2 protein localized to the nucleus as did the wild-type OTX2 protein, whereas the p.K74fsX103-OTX2 and p.A72fsX86-OTX2 proteins were incapable of localizing to the nucleus (Fig. 3B). The results were consistent with those of the Western blot analysis because nuclear extracts were used for the Western blotting, with some probable contamination of cytoplasm.

DNA binding analysis revealed that the p.G188X-OTX2 protein with nuclear localizing capacity bound to the wild-type OTX2 binding sites within the four promoters examined, including the *GNRH1* promoter, but not to the mutated OTX2 binding sites (Fig. 3C). The band shift

COLOR



FIG. 4. PCR-based human cDNA library screening for *OTX2* (35 cycles). A, Schematic representation of the *OTX2* isoform-a (NM_21728.2) and isoform-b (NM_172337.1). Because of the two alternative splice acceptor sites at the boundary between intron 3 and exon 4, isoform-a carries eight amino acids (shown in *gray*) in the vicinity of the HD, whereas isoform-b is lacking the eight amino acids. B, PCR amplification data. *OTX2* is clearly expressed in the pituitary and hypothalamus, with isoform-b being the major product. *GAPDH* has been used as an internal control. F, Fetus; A, adult.

was more obvious for the wild-type OTX2 protein than for the p.G188X-OTX2 protein, consistent with the difference in the molecular masses.

Transactivation analysis showed that the wild-type OTX2 protein had transactivation activities for the four promoters examined including the *GNRH1* promoter, whereas the p.K74fsX103-OTX2 and p.A72fsX86-OTX2 proteins had virtually no transactivation function, and the p.G188X-OTX2 protein had reduced (~50%) transactivation activities (Fig. 3D). The three mutant OTX2 proteins had no dominant-negative effects. In addition, the two missense p.A245V-OTX2 and p.T178S-OTX2 proteins had apparently normal transactivation activities with no dominant-negative effect (supplemental Fig. S2).

PCR-based expression analysis of *OTX2*

OTX2 expression was identified in the pituitary and the hypothalamus as well as in the brain and the thalamus but not detected in the spinal cord, kidney, leukocytes, and skin fibroblasts (Fig. 4). The isoform-b lacking the eight amino acids was predominantly expressed.

Clinical findings in *OTX2* mutation-positive patients

Clinical data are summarized in Table 1 (*left part*). Anophthalmia and/or microphthalmia was present in cases 1–5. Developmental delay was obvious in cases 1 and 3–5, whereas it was obscure in case 2 because of the young age. Prenatal growth was normally preserved in cases 1–5, whereas postnatal growth was compromised in cases 1, 3, and 5. Cases 1 and 5 had IGHD, and case 3 had CPHD (Table 2); furthermore, cases 1, 3, and 5 had pituitary hypoplasia (PH) and/or ectopic posterior pituitary (EPP) (supplemental Fig. S3). Case 3 showed no pubertal development at 15 yr of age (Tanner pubic hair stage 2 in Japanese boys: 12.5 ± 0.9 yr) (16). Cases 2 and 4 had no discernible pituitary dysfunction and did not receive magnetic resonance imaging examinations. In addition, case 1 had right retractile testis. Patient 1 with p.T178S had CPHD but without ocular anomalies, and patient 2 with p.A245V had bilateral optic nerve hypoplasia and short stature.

Discussion

We identified two frameshift mutations in cases 1 and 2 and a nonsense mutation in unrelated cases 3 and 4. Furthermore, it was predicted that these mutations neither affected splice patterns nor underwent NMD, although direct analysis using mRNA was impossible due to lack of detectable *OTX2* expression in already collected leukocytes as well as skin fibroblasts, which might be available from cases 1–4. Thus, these mutations are predicted to produce aberrant OTX2 proteins *in vivo* that were used in the *in vitro* functional studies. In this context, the functional studies indicated that the two frameshift mutations were amorphic and the nonsense mutation was hypomorphic. The results are consistent with the previous notion that the HD not only has DNA binding capacity but also retains at least a part of nuclear localization signal on its C-terminal portion and the TD primarily resides in the C-terminal region (17) (Fig. 1A). Whereas the two missense substitutions were absent in 100 control subjects, they would be rare normal variations rather than pathological mutations because of the normal transactivation activities with no dominant-negative effect.

We also detected a heterozygous microdeletion involving *OTX2* in case 5 that was not mediated by repeat sequences. This implies the importance of the examination of a microdeletion. Indeed, such a cryptic microdeletion has been identified in multiple genes with the development of MLPA that can serve as a screening method in the detection of microdeletions (18). Whereas the microdeletion of case 5 has removed 16 additional genes (Ensembl Genome Browser, http://www.ensembl.org/), the clinical phenotype of case 5 is explainable by *OTX2* haploinsufficiency alone. Thus, hemizygosity for the 16 genes would not have a major clinical effect, if any.

Furthermore, the present study revealed two findings. First, *OTX2* was expressed in the hypothalamus and had a transactivation function for the *GNRH1* promoter. This implies that *GNRH1* essential for the hypothalamic GnRH secretion is also a target gene of *OTX2*, as has been demonstrated in the mouse (15). Second, the short isoform-b was predominantly identified in the *OTX2* expression-positive tissues. This sug-

TABLE 1. Summary of clinical findings in patients with heterozygous *OTX2* mutations

	Present study					Previous studies[a]			
	Case 1	**Case 2**	**Case 3**	**Case 4**	**Case 5**	**Case 6**	**Case 7**	**Case 8**	**Case 9**
Present age (yr)	3	1	15	10	2	3	6	14	6
Sex	Male	Female	Male	Male	Male	Female	Male	Female	Male
Mutation[b]									
cDNA	c.221_236del	c.214_217del GCACinsCA	c.562G>T	c.562G>T	Whole gene deletion	c.402_403insC	c.674A>G	c.674A>G	c.405_406insCT
Protein	p.K74fsX103	p.A72fsX86	p.G188X	p.G188X	Absent	p. S135fsX136	p.N225S	p.N225S	p.S136fsX178
Function	Severe LOF	Severe LOF	Mild LOF	Mild LOF	Absent	Severe LOF	DN	DN	Severe LOF
Ocular malformation									
Right	AO	MO	MO	MO	MO	AO	N.D.	N.D.	AO
Left	MO	MO	MO	MO	AO	AO	N.D.	N.D.	AO
Developmental delay	+	Uncertain	+	+	+	+	N.D.	N.D.	+
Prenatal growth failure[c]	−	−	−	−	−	−	N.D.	N.D.	−
Birth length (cm) (SDS)	46.5 (−1.2)	48.3 (±0)	50 (+0.5)	49 (±0)	47.9 (−0.5)	50 (+0.6)	N.D.	N.D.	49.5 (+0.2)
Birth weight (kg) (SDS)	2.77 (−0.5)	3.22 (+0.6)	3.62 (+1.5)	3.23 (+0.5)	2.96 (−0.1)	3.16 (+0.2)	N.D.	N.D.	3.49 (+1.2)
Birth OFC (cm) (SDS)	32.5 (−0.7)	34 (+0.7)	N.E.	32.5 (−0.7)	31.5 (−1.4)	33.7 (+0.6)	N.D.	N.D.	N.D.
Postnatal growth failure[c]	+	−	+	−	+	+	+	+	+
Present height (cm) (SDS)	76.9 (−3.3)[d]	73.2 (±0)	114.0 (−4.1)[e]	130.8 (−1.5)	78.1 (−2.4)	85.0 (−3.3)	N.D.	N.D.	81.8 (−5.3)[f]
Present weight (kg) (SDS)	8.9 (−2.6)[d]	8.3 (−0.4)	16.8 (−2.4)[e]	23.2 (−1.6)	9.9 (−1.4)	10.1 (−2.6)	N.D.	N.D.	10.7 (−2.5)[f]
Present OFC (cm) (SDS)	N.E.	N.E.	N.E.	N.E.	N.E.	46 (−1.9)	N.D.	N.D.	47.2 (−2.7)[f]
Paternal height (cm) (SDS)[c]	160 (−1.9)	168 (−0.5)	178 (+1.2)	167 (−0.7)	163 (−1.3)	170 (±0)	178 (+0.3)	188 (+1.8)	N.D.
Maternal height (cm) (SDS)[c]	150 (−1.6)	151 (−1.3)	166 (+1.5)	165 (+1.4)	170 (+2.2)	155 (−0.6)	158 (−0.8)	168 (+0.7)	N.D.
Affected pituitary hormones	GH	No	GH, TSH, PRL, LH, FSH	No	GH	GH	GH, TSH, ACTH, LH, FSH	GH, TSH, ACTH, LH, FSH	GH, TSH, ACTH, LH, FSH
MRI findings									
Pituitary hypoplasia	+	N.E.	+	N.E.	+	−	+	+	+
EPP	+	N.E.	+	N.E.	−	−	+	−	+
Other features	Retractile testis (R)			Seizure		Cleft palate			Chiari malformation

SDS, SD score; OFC, occipitofrontal head circumference; MRI, magnetic resonance imaging; LOF, loss of function; DN, dominant negative; AO, anophthalmia; MO, microphthalmia; N.D., not described; N.E., not examined; PRL, prolactin; R, right.

[a] Case 6, Dateki *et al.* (8); cases 7 and 8, Diaczok *et al.* (9); case 9, Tajima *et al.* (10); [b] the cDNA and protein numbes are based on the human *OTX2* isoform-b (GenBank accession no. NM_172337.1), and the A of the ATG encoding the initiator methionine residue is denoted position +1; thus, the description of the mutations in cases 7–9 is different from that reported by Diaczok *et al.* (9) and Tajima *et al.* (10); [c] assessed by the age- and sex-matched Japanese growth standards (27) (cases 1–6 and 9 and their parents) or by the American growth standards (28) (the parents of cases 7 and 8); [d] at 2 yr 4 months of age before GH treatment; [e] at 10 yr of age before GH treatment; [f] at 4 yr of age before GH treatment.

Please change the position of (SDS) for the one line lower position.

Please change the position of (kg) for the right side of "Present weig

balt1/zeg-jcem/zeg-jcem/zeg00210/zeg7042-10z | xppws | S=1 | 11/24/09 | 9:20 | 4/Color Figure(s): F1–4 | Art: 09-1334 | Input-ss

Please change the position of (ng/dl) for the right side of "Testosterone".

TABLE 2. Blood hormone values in cases 1–5 with heterozygous *OTX2* mutations

Patient		Case 1		Case 2		Case 3		Case 4		Case 5	
Sex (age at examination)		Male (2 yr)		Female (1 yr)		Male (14 yr)		Male (10 yr)		Male (2 yr)	
	Stimulus (dose)	Basal	Peak	Basal	Peak	Basal	Peak	Basal	Peak	Basal	Peak
GH (ng/ml)	Insulin (0.1 U/kg)[a]	1.9[b]	**4.0**[b]	3.3[b]	N.E.	0.8[b]	**1.3**[b]	12.1[b]	N.E.	0.5[c]	**9.0**[c]
	Arginine (0.5 g/kg)									1.1[c]	**7.0**[c]
	L-dopa (10 mg/kg)	1.5[b]	**3.8**[b]			0.3[b]	**1.0**[b]				
LH (mIU/ml)	GnRH (100 μg/m^2)	0.1	1.7	0.1	N.E.	2.3[d]	**4.5**	0.4	N.E.	0.1	3.1
FSH (mIU/ml)	GnRH (100 μg/m^2)	1.0	6.2	3.7	N.E.	1.3[d]	**6.3**	1.1	N.E.	1.5	9.9
TSH (μU/ml)	TRH (10 μg/kg)	4.2	23.8	1.1	N.E.	0.2	**1.9**	1.1	N.E.	5.2	19.5
Prolactin (ng/ml)	TRH (10 μg/kg)	17.9	34.5	N.E.	N.E.	5.5	**8.3**	9.1	N.E.	10.43	88.8
ACTH (pg/ml)	Insulin (0.1 U/kg)	31	195	N.E.	N.E.	24		N.E.	N.E.	41	222
Cortisol (μg/dl)[d]	Insulin (0.1 U/kg)	12.7		9.4	N.E.	19.4		N.E.	N.E.	25.4	39.2
IGF-I (ng/ml)		**8**		65	N.E.	**5**		214	N.E.	48	
Testosterone (ng/dl)		N.E.		N.E.	N.E.	**45**		<5	N.E.	N.E.	
Free T_4 (ng/dl)		1.32		1.17	N.E.	**0.87**		1.15	N.E.	1.17	
Free T_3 (pg/ml)		2.91		3.24	N.E.	**1.94**		3.92	N.E.	4.54	

The conversion factor to the SI unit: GH, 1.0 (μg/liter); LH, 1.0 (IU/liter); FSH, 1.0 (IU/liter); TSH, 1.0 (mIU/liter); prolactin, 1.0 (μg /liter); ACTH, 0.22 (pmol/liter); cortisol, 27.59 (nmol/liter); IGF-I, 0.131 (nmol/liter); testosterone, 0.035 (nmol/liter); free T_4, 12.87 (pmol/liter); and free T_3, 1.54 (pmol/liter). Hormone values have been evaluated by the age- and sex-matched Japanese reference data (29, 30); low hormone data are *boldfaced*. Blood sampling during the provocation tests: 0, 30, 60, 90, and 120 min. N.E., Not examined.

[a] Sufficient hypoglycemic stimulations were obtained during all the insulin provocation tests; [b] GH was measured using the recombinant GH standard, and the peak GH values of 6 and 3 ng/ml are used as the cutoff values for partial and severe GH deficiency, respectively; [c] GH was measured by the classic RIA, and the peak GH values of 10 and 5 ng/ml were used as the cutoff values for partial and severe GH deficiency; [d] Obtained at 0800–0900 h.

gests that the biological functions of *OTX2* are primarily contributed by the short isoform-b.

Clinical features of cases 1–5 are summarized in Table 1, together with those of the previously reported *OTX2* mutation-positive patients examined for detailed pituitary function. Here four patients with cytogenetically recognizable deletions involving *OTX2* are not included (19–22) because the deletions appear to have removed a large number of genes including *BMP4* and/or *SIX6* (Fig. 2B) that can be relevant to pituitary development and/or function (1, 23).

Several points are noteworthy for the clinical findings. First, although cases 1–5 in this study had anophthalmia and/or microphthalmia, ocular phenotype has not been described in cases 7 and 8 identified by *OTX2* mutation analysis in 50 patients with hypopituitarism (9). Whereas no description of a phenotype would not necessarily indicate the lack of the phenotype, *OTX2* mutations may specifically affect pituitary function at least in several patients. This would not be unexpected because several *OTX2* mutation-positive patients are free from ocular anomalies (6).

Second, pituitary phenotype is variable and independent of the *in vitro* function data. This would be explained by the notion that haploinsufficiency of developmental genes is usually associated with a wide range of penetrance and expressivity depending on other genetic and environmental factors (24), although the actual underlying factors remain to be identified. In this regard, because direct mRNA analysis was not performed, it might be possible that the mutations have not produced the predicted aberrant protein and, consequently, *in vitro* function data do not necessarily reflect the *in vivo* functions. Even if this is the case, the quite different pituitary phenotype between cases 3 and 4 with the same mutation would argue for the notion that pituitary phenotype is independent of the residual OTX2 function.

Third, cases 1, 3, 5, and 6–9 with pituitary dysfunction have IGHD or CPHD involving GH, and show the combination of preserved prenatal growth and compromised postnatal growth characteristic of GH deficiency (25). This suggests that GH is the most vulnerable pituitary hormone in *OTX2* mutations. Consistent with this, previously reported patients with ocular anomalies and *OTX2* mutations also frequently exhibit short stature (6, 8). Thus, pituitary function studies are recommended in patients with ocular anomalies and postnatal short stature to allow for appropriate hormone therapies including GH treatment for short stature, cortisol supplementation at a stress period, T_4 supplementation to protect the developmental deterioration, and sex steroid supplementation to induce secondary sexual characteristics. Furthermore, *OTX2* mutation analysis is also recommended in such patients.

Lastly, PH and/or EPP is present in patients with IGHD and CPHD, except for case 6 with IGHD. In this regard, the following findings are noteworthy: 1) heterozygous loss-of-function mutations of *HESX1* are associated with

a wide phenotypic spectrum including CPHD, IGHD, and apparently normal phenotype and often cause PH and EPP, whereas homozygous *HESX1* mutations usually lead to CPHD as well as PH and EPP (2); 2) heterozygous loss-of-function mutations of *POU1F1* usually permit apparently normal pituitary phenotype, whereas homozygous loss-of-function mutations and heterozygous dominant-negative mutations usually result in GH, TSH, and prolactin deficiencies and often cause PH but not EPP (2); and 3) heterozygous *GNRH1* frameshift mutation are free from discernible phenotype, whereas homozygous *GNRH1* mutations result in isolated hypogonadotropic hypogonadism with no abnormal pituitary structure (26). Collectively, overall pituitary phenotype may primarily be ascribed to reduced *HESX1* expression, although reduced *POU1F1* and *GNRH1* expressions would also play a certain role, and there may be other target genes of *OTX2*.

In summary, the results imply that *OTX2* mutations are associated with variable pituitary phenotype, with no genotype-phenotype correlations, and that *OTX2* can transactivate *GNRH1* as well as *HESX1* and *POU1F1*. Further studies will serve to clarify the role of *OTX2* in the pituitary development and function.

Insert new words:Instability of the human genome: mutation and DNA repair. In:

Acknowledgments

We thank the patients and parents for participating in this study. We also thank Dr. Nicola Ragge and Dr. David J Bunyan for the MLPA probe sequence of *OTX2*.

Address all correspondence and requests for reprints to: Dr. T. Ogata, Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, 2-10-1 Ohkura, Setagaya, Tokyo 157-8535, Japan. E-mail: tomogata@nch.go.jp.

This work was supported by Grants-in-Aid for Young Scientists (B-21791025) from the Ministry of Education, Culture, Sports, Science, and Technology and Grants for Child Health and Development (20C-2); Research on Children and Families (H21-005); and Research on Measures for Intractable Diseases (H21-043) from the Ministry of Health, Labor, and Welfare.

Disclosure Summary: The authors have nothing to declare.

References

1. Cohen LE, Radovick S 2002 Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 23:431–442
2. Kelberman D, Dattani MT 2007 Hypopituitarism oddities: congenital causes. Horm Res 68(Suppl 5):138–144
3. Vieira TC, Boldarine VT, Abucham J 2007 Molecular analysis of PROP1, PIT1, HESX1, LHX3, and LHX4 shows high frequency of PROP1 mutations in patients with familial forms of combined pituitary hormone deficiency. Arq Bras Endocrinol Metab 51:1097–1103
4. Hever AM, Williamson KA, van Heyningen V 2006 Developmental malformations of the eye: the role of *PAX6*, *SOX2* and *OTX2*. Clin Genet 69:459–470
5. Courtois V, Chatelain G, Han ZY, Le Novère N, Brun G, Lamonerie T 2003 New Otx2 mRNA isoforms expressed in the mouse brain. J Neurochem 84:840–853
6. Ragge NK, Brown AG, Poloschek CM, Lorenz B, Henderson RA, Clarke MP, Russell-Eggitt I, Fielder A, Gerrelli D, Martinez-Barbera JP, Ruddle P, Hurst J, Collin JR, Salt A, Cooper ST, Thompson PJ, Sisodiya SM, Williamson KA, Fitzpatrick DR, van Heyningen V, Hanson IM 2005 Heterozygous mutations of *OTX2* cause severe ocular malformations. Am J Hum Genet 76:1008–1022
7. Wyatt A, Bakrania P, Bunyan DJ, Osborne RJ, Crolla JA, Salt A, Ayuso C, Newbury-Ecob R, Abou-Rayyah Y, Collin JR, Robinson D, Ragge N 2008 Novel heterozygous OTX2 mutations and whole gene deletions in anophthalmia, microphthalmia and coloboma. Hum Mutat 29:E278–E283
8. Dateki S, Fukami M, Sato N, Muroya K, Adachi M, Ogata T 2008 OTX2 mutation in a patient with anophthalmia, short stature, and partial growth hormone deficiency: functional studies using the IRBP, HESX1, and POU1F1 promoters. J Clin Endocrinol Metab 93:3697–3702
9. Diaczok D, Romero C, Zunich J, Marshall I, Radovick S 2008 A novel dominant-negative mutation of OTX2 associated with combined pituitary hormone deficiency. J Clin Endocrinol Metab 93:4351–4359
10. Tajima T, Ohtake A, Hoshino M, Amemiya S, Sasaki N, Ishizu K, Fujieda K 2009 OTX2 loss of function mutation causes anophthalmia and combined pituitary hormone deficiency with a small anterior and ectopic posterior pituitary. J Clin Endocrinol Metab 94:314–319
11. Cartegni L, Chew SL, Krainer AR 2002 Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298
12. Strachan T, Read AP 2004 Human molecular genetics. 3rd ed. London and New York: Garland Science; 334–337 AQ: B
13. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE 2004 Nonsense-mediated decay approaches the clinic. Nat Genet 36:801–808
14. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G 2002 Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
15. Kelley CG, Lavorgna G, Clark ME, Boncinelli E, Mellon PL 2000 The Otx2 homeoprotein regulates expression from the gonadotropin-releasing hormone proximal promoter. Mol Endocrinol 14:1246–1256
16. Matsuo N 1993 Skeletal and sexual maturation in Japanese children. Clin Pediatr Endocrinol 2(Suppl):1–4
17. Chatelain G, Fossat N, Brun G, Lamonerie T 2006 Molecular dissection reveals decreased activity and not dominant-negative effect in human OTX2 mutants. J Mol Med 84:604–615
18. den Dunnen JT, White SJ 2006 MLPA and MAPH: sensitive detection of deletions and duplications. Curr Protoc Hum Genet Chapter 7, Unit 7.14 AQ: C
19. Bennett CP, Betts DR, Seller MJ 1991 Deletion 14q (q22q23) associated with anophthalmia, absent pituitary, and other abnormalities. J Med Genet 28:280–281
20. Elliott J, Maltby EL, Reynolds B 1993 A case of deletion 14(q22.1→q22.3) associated with anophthalmia and pituitary abnormalities. J Med Genet 30:251–252
21. Lemyre E, Lemieux N, Décarie JC, Lambert M 1998 Del(14)(q22.1q23.2) in a patient with anophthalmia and pituitary hypoplasia. Am J Med Genet 77:162–165
22. Nolen LD, Amor D, Haywood A, St Heaps L, Willcock C, Mihelec M, Tam P, Billson F, Grigg J, Peters G, Jamieson RV 2006 Deletion at 14q22–23 indicates a contiguous gene syndrome comprising anophthalmia, pituitary hypoplasia, and ear anomalies. Am J Med Genet A 140:1711–1718
23. Zhu X, Lin CR, Prefontaine GG, Tollkuhn J, Rosenfeld MG 2005

Please see the comment in the letter.

Genetic control of pituitary development and hypopituitarism. Curr Opin Genet Dev 15:332–340
24. Fisher E, Scambler P 1994 Human haploinsufficiency — one for sorrow, two for joy. Nat Genet 7:5–7
25. Parks JS, Felner EI 2007 Hypopituitarism. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders Elsevier; 2293–2299
26. Bouligand J, Ghervan C, Tello JA, Brailly-Tabard S, Salenave S, Chanson P, Lombès M, Millar RP, Guiochon-Mantel A, Young J 2009 Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med 360:2742–2748
27. Suwa S, Tachibana K, Maesaka H, Tanaka T, Yokoya S 1992 Longitudinal standards for height and height velocity for Japanese children from birth to maturity. Clin Pediatr Endocrinol 1:5–13
28. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL 2002 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11 246:1–190
29. Japan Public Health Association 1996 Normal biochemical values in Japanese children (in Japanese). Tokyo: Sanko Press
30. Inada H, Imamura T, Nakajima R 2002 Manual of endocrine examination for children (in Japanese). Osaka: Medical Review

Please see the comment in the letter.

AQ: D

JOBNAME: AUTHOR QUERIES PAGE: 1 SESS: 1 OUTPUT: Tue Nov 24 09:20:55 2009
/balt1/zeg-jcem/zeg-jcem/zeg00210/zeg7042-10z

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES 1

A—Please provide manufacturer and location of RP11-56612 BAC probe.

B—Please provide last names and initials of editors and title of section of book of ref. 12.

C—If ref. 18 is a book, please provide full title of book, publisher, and city of publication.

D—Please verify volume number and page range added to ref. 26.

J Inherit Metab Dis
DOI 10.1007/s10545-009-9022-9

RAPID COMMUNICATION

A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy

Megumi Tsuji · Noriko Aida · Takayuki Obata · Moyoko Tomiyasu · Noritaka Furuya · Kenji Kurosawa · Abdellatif Errami · K. Michael Gibson · Gajja S. Salomons · Cornelis Jakobs · Hitoshi Osaka

Received: 2 October 2009 / Revised: 29 October 2009 / Accepted: 23 November 2009

Abstract
Background Deficiency of 4-aminobutyrate aminotransferase (GABA-T) is a rare disorder of GABA catabolism, with only a single sibship reported. We report on a third case, a Japanese female infant with severe psychomotor retardation and recurrent episodic lethargy with intractable seizures, with the diagnosis facilitated by proton magnetic resonance (MR) spectroscopy (^{1}H-MRS).
Methods Neuroimaging was performed at the first episode of lethargy. For ^{1}H-MRS, locations were placed in the semioval center and the basal ganglia. Quantification of metabolite concentrations were derived using the LCModel. We confirmed the diagnosis subsequently by enzyme and molecular studies, which involved direct DNA sequence analysis and the development of a novel multiplex ligation-dependent probe amplification test.
Results ^{1}H-MRS analysis revealed an elevated GABA concentration in the basal ganglia (2.9 mmol/l). Based on the results of quantitative ^{1}H-MRS and clinical findings, GABA-T deficiency was suspected and confirmed in cultured lymphoblasts. Molecular studies of the *GABA-T* gene revealed compound heterozygosity for a deletion of one exon and a missense mutation, 275G>A, which was not detected in 210 control chromosomes.
Conclusions Our results suggest that excessive prenatal GABA exposure in the central nervous system (CNS) was responsible for the clinical manifestations of GABA transaminase deficiency. Our findings suggest the dual

Communicated by: Marinus Duran

M. Tsuji · H. Osaka (✉)
Division of Neurology, Clinical Research Institute,
Kanagawa Children's Medical Center,
2-138-4 Mutsukawa, Minami-ku,
Yokohama 232-8555, Japan
e-mail: hosaka@kcmc.jp

N. Aida
Division of Radiology, Clinical Research Institute,
Kanagawa Children's Medical Center,
2-138-4 Mutsukawa, Minami-ku,
Yokohama 232-8555, Japan

N. Furuya · K. Kurosawa
Division of Genetics, Clinical Research Institute,
Kanagawa Children's Medical Center,
2-138-4 Mutsukawa, Minami-ku,
Yokohama 232-8555, Japan

T. Obata · M. Tomiyasu
Department of Biophysics, Molecular Imaging Center,
National Institute of Radiological Sciences,
Chiba, Japan

A. Errami
MRC-Holland,
Amsterdam, The Netherlands

K. M. Gibson
Department of Biological Sciences,
Michigan Technological University,
Houghton, MI, USA

G. S. Salomons · C. Jakobs
Metabolic Unit, Department of Clinical Chemistry,
VU University Medical Center,
Amsterdam, The Netherlands

H. Osaka
Molecular Pathology & Genetics Division,
Kanagawa Cancer Center Research Institute,
Yokohama, Japan

Published online: 06 January 2010

nature of GABA as an excitatory molecule early in life, followed by a functional switch to an inhibitory species later in development. Furthermore, quantitative ^{1}H-MRS appears to be a useful, noninvasive tool for detecting inborn errors of GABA metabolism in the CNS.

Abbreviations

GABA-T	Gamma aminobutyric acid transaminase
^{1}H-MRS	Proton magnetic resonance spectroscopy
CNS	Central nervous system
SSADH	Succinic semialdehyde dehydrogenase
GHB	4-hydroxybutyrate
EEG	Electroencephalogram
CSF	Cerebrospinal fluid
DWI	Diffusion-weighted image
Glx	Glutamine/glutamate complex

Introduction

Disorders of gamma aminobutyric acid (GABA) metabolism are rare and manifest prominent neurological sequelae; 4-aminobutyrate aminotransferase (γ-aminobutyrate: GABA transaminase, or GABA-T; OMIM 137150) deficiency is characterized by severe psychomotor retardation, hypotonia, hyperreflexia, seizures, high-pitched cry, and growth acceleration, associated with early infantile death in two siblings (one family) (Jaeken et al 1984; Jakobs et al 1993). Succinic semialdehyde dehydrogenase (SSADH) deficiency [or 4-hydroxybutyric (GHB) aciduria] is the most prevalent of the GABA degradation disorders and one in which pharmacologically active GHB, as well as GABA, accumulate in patient body fluids (Jakobs et al 1993; Pearl et al 2007). Homocarnosinosis (homocarnosine is the GABA:L-histidine



Fig. 1 Initial computed tomography (CT) and magnetic resonance imaging (MRI) findings at 8 months. Baseline CT (a), T1-weighted (b), T2-weighted (c), diffusion-weighted (d) axial MRI images, and apparent diffusion coefficients (ADC) map (e) at the level of the basal ganglia, and diffusion-weighted images (DWI) of the semioval center (f). CT (a) shows no particular abnormality, whereas T1-weighted (b) and T2-weighted (c) images suggest delayed myelination. Subcortical high white-matter signal on the T1-weighted image was not observed, and low signal on the T2-weighted image was limited to the posterior portion of the internal capsules and splenium of the corpus callosum. DWI (d, f) shows widespread high signals in the internal and external capsules and many parts of the subcortical white matter, with restricted diffusion (e)

conjugate) is very rare (two cases) and may represent an allelic form of carnosinase deficiency(Pearl et al 2007). Considering the inhibitory nature of GABA activity in the central nervous system (CNS), the paradoxical neurological phenomenon associated with seizures in cases of GABA excess is of interest. In this study, we detected elevated GABA in a patient by proton magnetic resonance spectroscopy (^{1}H-MRS) using the LCModel to quantify the spectra automatically. This method has potential application to neurological disorders such as GABA-T deficiency.

Case report

The patient was a Japanese female infant, born full term with normal delivery. She was the second child of healthy parents. There was no consanguinity or family history of neurological disorders. A 6-year-old sister was normal. Early infancy was unremarkable. At 7 months, she was evaluated for psychomotor retardation, hypotonia, bilateral intermittent esotropia, hyperreflexia, and positive Babinski reflex. There was no dysmorphy. At age 8 months, she was admitted with decreased consciousness 48 h after an acute febrile illness. Respiratory distress developed that required mechanical ventilation. Steroid pulse therapy was initiated for a suspected acute encephalopathy of unknown etiology. Segmental myoclonic jerks occurred and were difficult to control, but consciousness returned. Electroencephalography (EEG) revealed diffuse slow spike and wave discharges with 1- to 2-s periods of suppression. Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. Limb motor conduction velocities were



Fig. 2 LCModel outputs of in vivo proton magnetic resonance (MR) spectra from the basal ganglia (volume, 10–17.5 ml; TE/TR, 20–30/5000 ms; number of excitations 6). *Bold lines* indicate LCModel fitting, and *thin lines* indicate the original spectra. Patient with gamma aminobutyric acid transaminase (GABA-T) deficiency (8 months) (a), a control individual (7 months) (b). *Bold lines* in the *upper row* are the fitting curves of total spectra including all metabolites, and those in the *lower row* are fitting curves for GABA. The estimated absolute concentrations of GABA in patient and control are 2.9 and 0.8 mmol/l, respectively. Normal GABA spectrum exhibits a quintet ($^3CH_2$) at 1.89 ppm, a triplet ($^4CH_2$) at 2.28 ppm, and a multiplet resembling a triplet ($^2CH_2$) at 3.01 ppm(Govindaraju et al 2000)